Researchers from The University of Texas MD Anderson Cancer Center have developed a first-in-class antibody that targets a protein overexpressed in many cancer types, allowing for the creation of a new radio-theranostic treatment that brings targeted radiation directly to tumor cells. The work is published in Theranostics.
This article was originally published on MedicalXpress.com

